

1
2
3 **Title:** Covid-19 vaccination intentions among Canadian parents of 9-12 year old children: results from
4
5 the All Our Families longitudinal cohort
6
7
8
9

10 **Authors:**

11 Erin Hetherington, PhD ^{1,2}, Sarah A Edwards, PhD ³, Shannon E MacDonald, PhD RN ^{4,5}, Nicole Racine,
12
13 PhD ^{6,7}, Sheri Madigan, PhD ^{6,7}, Sheila McDonald, PhD* ⁴, Suzanne Tough, PhD* ^{3,4,7}
14
15

16 * Contributed equally as co-senior authors
17
18
19
20

21 **Affiliations:**

- 22
23 1) Department of Obstetrics & Gynaecology, Cumming School of Medicine, University of Calgary
24
25 2) Department of Epidemiology, Biostatistics & Occupational Health, McGill University
26
27 3) Department of Community Health Sciences, Cumming School of Medicine, University of Calgary
28
29 4) Department of Pediatrics, Cumming School of Medicine, University of Calgary
30
31 5) Faculty of Nursing, University of Alberta
32
33 6) Department of Psychology, University of Calgary
34
35 7) Alberta Children's Hospital Research Institute
36
37
38
39
40

41 **Correspondence:** Erin Hetherington, Foothills Medical Centre, 4th Floor North Tower, 1403 29 Street
42
43 NW, Calgary, Alberta, Canada T2N 2T9. elhether@ucalgary.ca 403-971-9512.
44
45
46
47

48 **Conflict of Interest:** The authors have no conflicts of interest relevant to this article to disclose.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Funding:** Funding for this project was provided by the Canadian Institutes for Health Research COVID-19
4
5 Rapid Research Funding Opportunity. The All Our Families Cohort is funded through Alberta Innovates
6
7 Interdisciplinary Team Grant #200700595.
8
9

10
11
12 **Role of the Funder:** The funder/sponsor did not participate in the work.
13
14
15

16
17 **Data sharing:** Individual, de-identified data are available to researchers who provide a methodologically
18
19 sound proposal for research. Inquires regarding access to data dictionaries, study protocols and
20
21 questionnaires may be made at: <https://allourfamiliesstudy.com/data-access/>
22
23
24

25 **Contributor's Statement:**

26
27 Drs Hetherington and Edwards conceptualized and designed the study and data collection instruments,
28
29 acquired funding, analysed the data and wrote the initial manuscript. Drs. MacDonald and Tough
30
31 conceptualized and designed the study and acquired funding, coordinated and supervised data
32
33 collection on this study and the historical cohort study, and reviewed and revised the manuscript. Drs.
34
35 Racine, MacDonald and Madigan assisted in the interpretation of results and critically reviewed and
36
37 revised the manuscript. All authors approved the final manuscript as submitted and agree to be
38
39 accountable for all aspects of the work.
40
41
42
43
44

45 **Acknowledgments:** The authors acknowledge the All Our Families research team and thank the
46
47 participants who took part in the study.
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background: Acceptance of a COVID-19 vaccine is critical to achieving high levels of immunization. The objective of this study is to understand factors associated with COVID-19 vaccine intentions among parents and explore reasons underlying decision making.

Methods: Participants from a longitudinal cohort were invited to participate in a COVID-19 impact survey in May-June 2020 (n=1321). Parents were asked about the impact of the pandemic and their intention to vaccinate their child against COVID-19 should a vaccine be approved. Past infant vaccination status was validated against public health records. Multinomial regression models were run to estimate associations between demographic factors, past vaccination status, and vaccine intention. Qualitative responses regarding factors impacting decision making were analyzed thematically.

Results: Sixty percent of parents (n=798) intended to vaccinate their children, but 9% (n=113) said they did not intend to vaccinate and 31% (n=410) were unsure. Lower education and income were inversely associated with intention to vaccinate. Incomplete vaccination history was associated with intention not to vaccinate but not uncertainty. Qualitative responses revealed concerns over vaccine safety and efficacy, long term effects and a rushed vaccination process.

Interpretation: Almost a third of parents remain unsure about vaccinating their children against COVID-19, even within a group with historically high uptake of infant vaccines. Given the many uncertainties about future COVID-19 vaccines, clear communication regarding safety will be critical to ensuring vaccine uptake.

Introduction

In Canada, as of November 2020, there have been more than 300,000 people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and over 10,000 deaths due to Coronavirus disease 2019 (COVID-19), with over 1 million deaths worldwide.^{1, 2} Given the devastating human, economic and social cost of the pandemic, the development of a vaccine remains a critical strategy to mitigate its impact.³ However, the development of a vaccine is not sufficient, as modeling suggests that up to 80% of the population needs to receive a vaccine that is 70% effective in order to end the pandemic without additional non-pharmaceutical interventions (e.g. physical distancing, masks, etc).⁴ Vaccine uptake relies on adequate production and distribution, but also on high levels of vaccine acceptance among the general public.⁵

Emerging studies with adults suggest that 60-80% are willing to receive a COVID-19 vaccine and 10% are not, with the remaining being unsure.⁵⁻⁸ Older age, higher education and higher income are associated with increased willingness to be vaccinated for COVID-19.⁵⁻⁷ In Canada, the National Advisory Committee on Immunization (NACI) has identified prioritized groups for early COVID-19 immunization.⁹ While NACI doesn't currently identify children as a priority population unless they have other underlying risk factors, they will be eligible for vaccination once sufficient vaccine supply is available. If the evolving evidence finds that children are important transmitters of infection to more vulnerable populations, and if COVID-19 disease transmission within schools continues to grow, vaccination of children will become increasingly important. Understanding what factors impact parental decision-making prior to vaccine roll-out is critical for early engagement with parents about COVID-19 vaccine intentions and ensuring adequate uptake for COVID-19 infection control. A limited number of cross-sectional studies, primarily outside of Canada, have asked if parents would be willing to vaccinate their children, with acceptance ranging from 65% to 75%, but motivations for not vaccinating remain understudied.¹⁰⁻¹² Past practices around vaccination may be critical to understanding barriers to uptake. Using longitudinally collected

1
2
3 data provides the most accurate description of past vaccination behaviour. Moreover, understanding
4
5 what factors influence decision-making will be critical to understanding how to communicate about a
6
7 potential new vaccine. Thus, the objectives of this study are to understand parents' COVID-19 vaccine
8
9 intentions, using longitudinal data including historically collected vaccination information and
10
11 demographic factors, and to explore reasons for and against COVID-19 vaccination.
12
13

14 **Methods**

15
16 *Participants.* This study used data from the longitudinal cohort study All Our Families in Alberta, Canada.
17
18 Cohort characteristics and study design are described in detail elsewhere.¹³ Briefly, the All Our Families
19
20 Cohort is a population-based pregnancy cohort that began in 2008 and recruited over a three year
21
22 period. Of the 3388 women originally enrolled, 2455 remain part of the study after 12 years (72%). From
23
24 May-June 2020, All Our Families participants, whose children had reached ages 9-12 years, were invited
25
26 to complete the COVID-19 impact survey. Of the 2455 eligible participants, 1321 responded (53.8%).
27
28 This study received ethical approval from the Conjoint Research Ethics Board of the University of
29
30 Calgary.
31
32

33
34 *Measures.* The COVID-19 Impact survey asked a series of questions about COVID-19 infection, job loss,
35
36 and the impact of school closures and physical isolation measures on mental health and social
37
38 connections. Participants reported on vaccine intentions for their All Our Families child. Specifically,
39
40 participants were asked: "If a COVID-19 vaccine is approved, would you vaccinate your child?" (no, yes,
41
42 unsure). Participants had the opportunity to provide a narrative response on what would impact their
43
44 decision to vaccinate using an open text box. Participant responses were linked to previously collected
45
46 longitudinal data on child's past infant vaccine status at age 2 and demographic characteristics. Vaccine
47
48 coverage at age 2 was collected via parental report and validated against administrative public health
49
50 records.¹⁴ Vaccine status at this age was categorized as "partially or not vaccination" or "complete
51
52 vaccination", according to the infant vaccine schedule in Alberta.
53
54
55
56
57
58
59
60

1
2
3 *Data Analysis.* Descriptive statistics on demographic characteristics and responses to the COVID-19
4 impact survey of the sample are provided. To describe which families were least likely to vaccinate, or
5 unsure whether to vaccinate, we estimated bivariate multinomial regression models to describe
6 unadjusted associations between participant characteristics and intention to vaccinate their child
7 against COVID-19. A complete case analysis was used due to low missing data (<1%). The reference
8 category was 'intend to vaccinate'. All quantitative analyses were carried out using SAS version 9.4. In
9 order to understand the factors impacting vaccine intentions, the qualitative data from narrative
10 responses were analysed. Responses were coded thematically, and then the coding scheme and analysis
11 was validated in a random sample of 20% of responses by a second author. If participants cited more
12 than one reason, their answers were coded to multiple categories.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 **Results**

29
30 *Quantitative results:* Participant characteristics stratified by vaccine intention are shown in Table 1.
31
32
33

34 (Insert Table 1)
35
36
37
38
39

40 Approximately 60% (n=798) of participants reported that they intended to give their 9-12 year old child
41 the COVID-19 vaccine, 9% (n=113) would not, and 31% (n=410) were unsure. The mean age of mothers
42 was 42 years, and 82% had a completed post-secondary degree or higher. Fifteen percent of children of
43 participants had partial or no vaccinations at age 2 (12.0% and 3.2%, respectively). Only 1.1% of families
44 had a confirmed COVID-19 infection at the time of the survey, while another 5.0% had a suspected case.
45
46
47
48
49
50
51 Multinomial analyses linking factors to vaccine intention status are shown in Table 2 with statistically
52 significant results (p<0.05 in bold).
53
54
55
56
57
58
59
60

1
2
3 (Insert Table 2)
4
5
6
7
8
9
10
11
12

13 Lower socio-economic status was associated with vaccine intention, with a stronger association for
14 those who do not intend to vaccinate, compared to those who are unsure. Participants with less
15 education were more likely to not want to vaccinate (OR 2.80, 95% CI 1.78, 4.40) or be unsure (OR: 1.98,
16 95%CI 1.47, 2.71). A similar pattern was seen for income. History of partial or non-vaccination was
17 associated with intent to not to vaccinate (OR 2.81, 95%CI:1.78, 4.40). There was no association
18 between vaccination history and uncertainty regarding a COVID-19 vaccine (OR 1.29, 95%CI: 0.92, 1.80).
19
20
21
22
23
24
25
26
27
28

29 *Qualitative results:* Eighty-five percent of participants provided a response in the narrative text box
30 asking about reasons underlying vaccine intention. Thematic analysis revealed ten primary factors
31 influencing decision-making were identified among all parents, regardless of intention to vaccinate.
32 Percent of respondents in each category (yes, no, unsure) listing a specific factor and are presented in
33 Figure 1. The inter-rater agreement for the categorization of narrative responses into themes was 82%
34 (kappa 0.76).
35
36
37
38
39
40
41
42
43
44

45 (Insert Figure 1)
46
47
48

49 A description of each theme, and example quotes are provided in Table 3.
50
51
52

53 (Insert Table 3)
54
55
56
57
58
59
60

1
2
3 The most common factor mentioned was “safety and efficacy”, which included concerns about potential
4 side-effects of vaccination. However, those intending not to vaccinate were more likely to mention long
5 term safety (36%) than general safety and efficacy (29%). In addition, concerns regarding the rushed
6 nature of testing which could potentially compromise the safety of the vaccine was cited among all
7 groups (yes: 6%, no: 22% and unsure: 17%). Personal health conditions were noted among those
8 intending to vaccinate (8%) those not intending to vaccinate (10%) and those who were unsure (6%).
9
10 Four percent of participants overall mentioned their attitude toward the influenza vaccine impacting
11 their thoughts on a COVID-19 vaccine but to differing degree (2% among yes, 9% among no, and 6%
12 among unsure). For example, some who were unsure said they thought the influenza vaccine was
13 ineffective, however, some intending to vaccinate said they got their flu shot every year and would also
14 get a COVID-19 vaccine. Among those not intending to vaccinate, or unsure, belief that the COVID-19
15 disease was not very severe, or that the pandemic would be over soon, were also factors cited in their
16 decision making.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **Interpretation**

36 Among families for with generally high levels of complete infant vaccinations, 31% reported they were
37 unsure and 9% reported they would not vaccinate their child against COVID-19. Findings from both the
38 quantitative and qualitative analysis suggest three key messages outlined in detail below. First,
39 incomplete infant vaccination was associated with negative intentions towards a COVID-19 vaccine, but
40 not uncertainty. Second, attitudes towards a COVID-19 vaccine may reflect growing uncertainty about
41 vaccine testing and development. Third, clear communication around the COVID-19 vaccine will be
42 critical to assuage fears about a novel vaccine. While children may not be among the first to receive
43 COVID-19 vaccinations in Canada, understanding parental motivations remains critical for ensuring high
44 uptake once a vaccine is rolled out for this age group.⁹
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Families characterized by less education and income were more likely to have negative or uncertain
4 intentions towards vaccinating their child against COVID-19, consistent with studies on COVID-19
5 vaccine intentions in adults.⁶⁻⁸ A history of partial or incomplete infant vaccination, was associated with
6 not wanting to vaccinate against COVID-19. Our findings are consistent with a multi-country study which
7 found that having their child up to date on childhood vaccines was associated with COVID-19 vaccine
8 acceptance in parents.¹² Our study expands this knowledge by showing that having complete infant
9 vaccinations was not associated with COVID-19 vaccine uncertainty. Interestingly, approximately 4% of
10 participants mentioned that their thinking about a COVID-19 vaccine was influenced by their attitude
11 toward the influenza vaccine, with both positive and negative opinions. This suggests that attitudes
12 towards the influenza vaccine are more salient than attitudes toward childhood vaccines when it comes
13 to COVID-19 vaccine intentions. The influenza vaccine has historically had lower uptake than childhood
14 vaccines.¹⁵ Given the very high proportion of parents who remain uncertain about a COVID-19 vaccine,
15 reliance on parental attitudes toward childhood vaccinations may not be sufficient for broad uptake of a
16 COVID-19 vaccine.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37 The qualitative data showed that the majority of families had concerns around safety and efficacy of the
38 vaccine, which has been noted previously.¹⁰ However, responses from “no” and “unsure” participants
39 specifically mentioned concerns around long term safety. Among those not intending to vaccinate, 36%
40 cited long term safety compared to 29% noting general safety concerns. Respondents noted the need
41 for years of testing or a guarantee of 100% safety which may reflect unrealistic expectations for
42 vaccines.^{16, 17} Polarization regarding vaccines is increasingly common, and has been linked with political
43 ideology and general skepticism of science in both Europe and the United States.^{6, 18, 19} In Canada,
44 vaccine hesitancy has increased in recent years and careful engagement with those who may be
45 uncertain about vaccines is recommended.²⁰ Moreover, only 1% of “no’s” and 2% of “unsure’s”

1
2
3 mentioned willingness to rely on the recommendation from a doctor or public health authority,
4 compared to 8% of “yeses”. Longer term engagement with non-combative strategies involving health
5 care providers and public health leaders may be critical for reengaging those who remain skeptical
6 about vaccines.²⁰
7
8
9

10
11
12
13
14 Finally, among those who did not intend to vaccinate, or were unsure, a considerable number cited
15 mistrust or concern with the rushed nature of testing. With increasing focus on novel vaccine types and
16 preliminary promising findings with novel types of vaccines, there is a need to effectively communicate
17 about the development, safety and efficacy of these vaccines.^{16, 21} And while these new developments
18 may hold promise, the consequences on overall vaccine confidence could be severely threatened if
19 novel vaccines have unintended consequences.^{22, 23} Due to the scope of the pandemic, vaccine trials are
20 increasingly being highlighted in mainstream media and data from Canada and Australia suggests that
21 acceptance of a new COVID-19 vaccine is declining over time.^{24, 25} Clear communication around risks and
22 benefits will be critical and research into effective communication strategies around novel vaccines is
23 urgently needed.^{16, 26}
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 This study may have limited generalizability due to participant characteristics and response rate (54%).
40 Responders were generally more affluent and more educated than non-respondents, and our sample
41 reflected a population with generally higher complete infant vaccination than the average in Alberta or
42 other Canadian provinces.^{27, 28} This would likely underestimate attitudes against a COVID-19 vaccine and
43 could bias associations towards the null. Moreover, data were collected in the first wave of COVID-19
44 (May-June 2020) and attitudes toward vaccine intentions may change over the course of the pandemic.
45 We only had validated information for vaccination status up to age 2. While 85% of participants
46 indicated that their child’s vaccines were complete by age 2, this might have dropped off if we had
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 complete data on pre-school vaccination status. We also did not have recent information on flu vaccine
4
5 uptake, which has been associated with COVID-19 vaccine studies in adults.⁷ Follow-up research will
6
7 more carefully assess influenza vaccine attitudes as well as the how parents view the risks of COVID-19
8
9 infection compared to a novel COVID-19 vaccine.
10

11
12
13
14 Families with lower income or lower education may be more reluctant to accept a COVID-19 vaccine.
15

16 Complete infant vaccination was not associated with uncertainty about a COVID-19 vaccine, suggesting
17
18 parents may view a novel COVID-19 vaccine differently from traditional infant immunizations.
19

20
21 Moreover, our population had higher average rates of complete infant vaccination, suggesting that
22
23 positive COVID-19 vaccination intentions may be even lower than our reported 60%. In order to
24
25 maximize children's uptake of a COVID-19 vaccine, assuaging parents' concerns regarding safety,
26
27 efficacy and testing appears to be paramount. Targeted public health strategies that include clear
28
29 communication about safety and efficacy, may increase acceptance. Emphasis on quality of scientific
30
31 evidence may be particularly salient among parents who are unsure.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Canada Go. Coronavirus disease 2019 (COVID-19): Epidemiology update Nov 15, 2020. Accessed November 16, 2020. <https://health-infobase.canada.ca/src/data/covidLive/Epidemiological-summary-of-COVID-19-cases-in-Canada-Canada.ca.pdf>
2. World Health Organization. Coronavirus disease (COVID-19) Update. World Health Organization. Accessed November 16, 2020. <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201005-weekly-epi-update-8.pdf>
3. Graham BS. Rapid COVID-19 vaccine development. *Science*. 2020;368(6494):945-946.
4. Bartsch SM, O'Shea KJ, Ferguson MC, et al. Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. *American journal of preventive medicine*. 2020;59(4):493-503.
5. Neumann-Böhme S, Varghese NE, Sabat I, et al. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. *The European Journal of Health Economics*. 2020;21:997-982.
6. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? *Vaccine*. 2020;38(42):6500-6507.
7. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes toward a potential SARS-CoV-2 vaccine: a survey of US adults. *Annals of internal medicine*. 2020;
8. Dodd RH, Cvejic E, Bonner C, Pickles K, McCaffery KJ. Willingness to vaccinate against COVID-19 in Australia. *The Lancet Infectious Diseases*. 2020;
9. National Advisory Committee on Immunization. Preliminary guidance on key populations for early COVID-19 immunization Public Health Agency of Canada. Accessed November 20 2020. <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-key-populations-early-covid-19-immunization.html>
10. Dror AA, Eisenbach N, Taiber S, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. *European journal of epidemiology*. 2020;35(8):775-779.
11. Pogue K, Jensen JL, Stancil CK, et al. Influences on attitudes regarding potential COVID-19 vaccination in the United States. *Vaccines*. 2020;8(4):582.
12. Goldman RD, Yan TD, Seiler M, et al. Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey. *Vaccine*. 2020;38(48):7668-7673.
13. Tough SC, McDonald SW, Collisson BA, et al. Cohort profile: the All Our Babies pregnancy cohort (AOB). *International Journal of Epidemiology*. 2017;46(5):1389-1390k.
14. Rafferty E, Hetherington E, Tough S, et al. The impact of time since vaccination and study design on validity in parental recall of childhood vaccination status in the All Our Families cohort. *Vaccine*. 2018;36(21):2953-2959.
15. Kempe A, Saville AW, Albertin C, et al. Parental hesitancy about routine childhood and influenza vaccinations: a national survey. *Pediatrics*. 2020;146(1)
16. Gellin B. Why vaccine rumours stick—and getting them unstuck. *The Lancet*. 2020;396(10247):303-304.
17. Sokol RL, Grummon AH. COVID-19 and Parent Intention to Vaccinate Their Children Against Influenza. *Pediatrics*. 2020;
18. Kennedy J. Populist politics and vaccine hesitancy in Western Europe: an analysis of national-level data. *European journal of public health*. 2019;29(3):512-516.
19. Ali K, Celentano L. Addressing vaccine hesitancy in the 'Post-Truth' era. *Eurohealth*. 2017;23(4):16-20.
20. Dubé E, Gagnon D, Ouakki M, et al. Understanding vaccine hesitancy in Canada: results of a consultation study by the Canadian Immunization Research Network. *PloS one*. 2016;11(6):e0156118.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
21. Shin MD, Shukla S, Chung YH, et al. COVID-19 vaccine development and a potential nanomaterial path forward. *Nature nanotechnology*. 2020;15(8):646-655.
22. Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. *European journal of epidemiology*. 2020;35(4):325-330.
23. Torreele E. The rush to create a covid-19 vaccine may do more harm than good. *bmj*. 2020;370
24. Rhodes A, Hoq M, Measey M-A, Danchin M. Intention to vaccinate against COVID-19 in Australia. *The Lancet Infectious Diseases*. 2020;
25. Angus Reid Institute. *Vacillate or Vaccinate? Fewer than half of Canadians say they'd get a COVID-19 inoculation as soon as possible*. 2020. Accessed October 15, 2020. <http://angusreid.org/covid19-vaccine-october/>
26. Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger JA. Vaccine hesitancy: an overview. *Human vaccines & immunotherapeutics*. 2013;9(8):1763-1773.
27. Bell CA, Simmonds KA, MacDonald SE. Exploring the heterogeneity among partially vaccinated children in a population-based cohort. *Vaccine*. 2015;33(36):4572-4578.
28. Dummer TJ, Cui Y, Strang R, Parker L. Immunization completeness of children under two years of age in Nova Scotia, Canada. *Canadian Journal of Public Health*. 2012;103(5):e363-e367.

Confidential


Table 1: Characteristics of parents' their intention to have their child receive the COVID19 vaccine

	Overall (N = 1,321) n (%)^a	Yes (N=798) n (%)	No (N=113) n (%)	Unsure (N = 410) n (%)
Maternal Age (mean, sd) – range 28-57	42.2 (4.4)	42.5 (4.1)	41.9 (4.7)	41.5 (4.7)
Maternal Education (high school or less) ^b	236 (17.9)	106 (13.3)	34 (30.1)	96 (23.5)
Family Income (<\$80,000) ^{a, c}	198 (15.1)	97 (12.8)	29 (26.1)	72 (17.7)
Marital Status (Single/Divorced/Separated/Widowed) ^{c, d}	69 (5.5)	42 (5.5)	7 (6.4)	20 (5.1)
Ethnicity (self-identified minority) ^e	221 (16.8)	132 (16.6)	20 (19.9)	69 (17.0)
Child vaccine history (partial/not vaccinated) ^f	200 (15.1)	102 (12.8)	33 (29.2)	65 (15.9)
COVID19 Infection (Yes/Maybe) ^g	80 (6.1)	54 (6.8)	7 (6.2)	19 (4.7)
a) slight variation in the denominator due to missing data on income or marital status (<1%); b) ref: some post secondary/completed college/undergraduate or higher; c) ref: family income (≥\$80,000); d) ref: married/common-law; e) ref: self-identified White; f) ref: complete vaccines at 2 years; g) ref: Not infected				

Table 2: Odd Ratios (OR) from multinomial models for parents reporting their intention to have their child receive the COVID19 vaccine.

	No vs. Yes OR (95% CI)	Unsure vs. Yes OR (95% CI)
Maternal Age (mean, sd) ^a	0.97 (0.93, 1.01)	0.94 (0.92, 0.97)
Maternal Education (high school or less) ^b	2.80 (1.78, 4.40)	1.98 (1.47, 2.71)
Family Income (<\$80,000) ^c	2.53 (1.58, 4.06)	1.53 (1.10, 2.14)
Marital Status ^d (Single/Divorced/Separated/Widowed)	1.16 (0.51, 2.66)	0.91 (0.53, 1.58)
Ethnicity (self-identified minority) ^e	1.09 (0.65, 1.83)	1.02 (0.74, 1.41)
Child vaccine history (partial/not vaccinated) ^f	2.81 (1.78, 4.40)	1.29 (0.92, 1.80)
COVID19 Infection (Yes/Maybe) ^g	0.91 (0.40, 2.05)	0.67 (0.39, 1.15)
All ORs represent bivariate associations and are unadjusted for other factors. a) increasing in years; b) ref: completed college/undergraduate or higher; c) ref: family income (≥\$80,000); d) ref: married/common-law; e) ref: self-identified White; f) ref: complete vaccines at 2 years; g) ref: Not infected Statistically significant results are presented in bold .		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Factors influencing vaccine intentions as thematically coded from narrative responses. Percentages are within each intention category (i.e. 48% of those intending to vaccinate mentioned the first theme, safety and efficacy). Categories are not mutually exclusive and may add up to more than 100%

Table 3: Quotes for qualitative categories.

Factor	Quotes
Safety and efficacy	<p>“The effectiveness of the vaccine is key to consider and any side effects.”</p> <p>“I believe in vaccinations so would lead toward vaccinating - but would need more scientific information before making the final decision.”</p>
Supportive of vaccines	<p>“would 100% vaccinate my family as soon as possible, we 100% support vaccinations.”</p> <p>“I believe in vaccines, I believe in science.”</p>
Long term safety	<p>“Trial period will be too short to predict all possible long-term risks. if a few years, maybe consider, definitely not within 1-2 years.”</p> <p>“I am hesitant to take a vaccine or have my child injected with a vaccine that is so new. I would be afraid of complications in futures years that are now unknown.”</p>
Rushed process /Scientific quality	<p>“It's safety. It seems like this vaccine is being rushed through trials.”</p> <p>“I trust medicine and science and have always vaccinated in the past; my only hesitancy with this vaccine would be the 'desperation/rush' that everyone is looking for a 'cure/solution' to COVID”</p>
Perception of personal risk	<p>“I am immune compromised so the family will be getting it to protect my health”</p> <p>“If we have any underlying health issues that would compromise our immune system.”</p> <p>“I will not be receiving vaccine because I feel it's useless to us, we are strong enough to get over this flue,”</p>
Recommendation from doctor or health authority	<p>“The recommendation of the Public Health Agency of Canada .”</p> <p>“My doctor's recommendation would be the only opinion I would use to make my decision about being vaccinated.”</p>
Perception of risk from COVID-19	<p>“Risk of contracting Covid-19 would need to be greater than any risk associated to the vaccine.”</p> <p>“How much of the virus is still going on and impacting society.”</p>
Availability and cost	<p>“Availability. I would pay for it if it was reasonable and available in my city.”</p> <p>“Availability and ease of access - I would not want to be standing in huge long lines for hours waiting for the vaccine like I did with H1N1.”</p>
Attitude towards flu vaccine (both positive and negative)	<p>“My child has had all of the childhood vaccines but our family does not obtain the influenza vaccine as I feel we are all very healthy.”</p> <p>“Like the flu shot, is it really going to get the right strand of COVID-19?”</p> <p>“We get the flu shot each year to protect our family from the worst of the effects of the flu.”</p>
Against vaccinations	<p>“I would not get the vaccine or give it to my children. If there were any measures to make the vaccine mandatory or if people with the vaccine were given preferential treatment it would further solidify my stance to not get the vaccine. The other factor that would affect my decision is the overbearing influence on WHO, Health Canada/PHAC and AHS from corporate entities.”</p> <p>“Nothing will impact or change my view to vaccinate. I will not vaccinate anyone in my family”</p>
Other (mandatory, family opinions)	<p>“If it is mandatory for work and school”</p> <p>“My ex husband is not for vaccines. This will be my challenge.”</p>

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1 3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	5 n/a
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	6 n/a 6 6 n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	5 5
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	6 6 5
Outcome data	15*	Report numbers of outcome events or summary measures over time	6

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7
2			(b) Report category boundaries when continuous variables were categorized	7
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
4	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
5	Discussion			
6	Key results	18	Summarise key results with reference to study objectives	10
7	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
8	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-13
9	Generalisability	21	Discuss the generalisability (external validity) of the study results	12
10	Other information			
11	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.